An immobilized perylene diimide derivative for fucoidan purification from a crude brown algae extract

A spectroscopic response factor-based toluidine blue assay towards a universal assay protocol for sulfated polysaccharides: Application to fucoidan content in crude extract

Sulfated polysaccharides (SPS) have attracted a lot of interest because of their diverse pharmacological functions. Numerous scientific studies have shown that SPS exhibit better biological activity than those that are not sulfated, such as immunomodulatory, anti-viral, and antioxidant activities. A crucial step to a better understanding of the mechanism of action and health effects is the production of high purity SPS. This calls for the development of selective assay techniques that can identify SPS preferentially without being influenced by other substances or the co-extracted polysaccharides. A universal modified toluidine blue (TB) assay was developed in this study to detect SPS. The assay procedures were conducted using different SPS standards including fucoidans from different biogenic sources, in addition to heparin and dextran sulfate. Spectroscopic response factor was calculated for each SPS which showed very good correlation (R2 = 0.998) with the corresponding sulfation degree. The proposed method was applied for determination of SPS content of crude fucoidan product using five different SPS standards. The method was cross validated by conducting ANOVA test to the obtained % recovery revealing that there is no significant difference between the results obtained by identical reference standard and four nonidentical natural SPS standards. This is the first report of a selective universal assay of SPS that enables the selective determination of SPS using a nonidentical reference standard.

Fucoidan, a brown seaweed polysaccharide in nanodrug delivery

Fucoidan-a sulfated marine seaweed obtained from brown algae-has raised considerable interest in the scientific community over the last decade as it possesses a wide range of biological activities such as antioxidant, antiviral, anti-inflammatory, anticoagulant, antithrombotic, anticarcinogenic, and immunoregulatory. This polysaccharide finds application as a drug delivery vehicle due to its non-cytotoxicity, biocompatibility, and biodegradability. Besides, nano biomedical systems have used this marine alga for diagnostic and therapeutic purposes. Fucoidan has been extensively studied for use in regenerative medicines, in wound healing, and for sustained drug delivery due to its large biodiversity, cost-effectiveness, and mild procedures for extraction and purification. However, the main concern that limits its application is the variance in its batch-to-batch extraction owing to species type, harvesting, and climatic factors. The current review encloses a compendious overview of the origin, chemical structure, and physicochemical and biological properties of fucoidan and its significant role in nanodrug delivery systems. Special emphasis is given to the recent advances in the use of native/modified fucoidan, its combination with chitosan and metal ions for nanodrug delivery applications, especially in cancer treatment. Additionally, use of fucoidan in human clinical trials as a complementary therapeutic agent is also reviewed.

Fucoidan mitigates gastric ulcer injury through managing inflammation, oxidative stress, and NLRP3-mediated pyroptosis

This study aimed to elucidate the gastro-protective effect of fucoidan against ethanol-induced gastric ulcer mediated via NLRP3-induced pyroptosis as an underlying mechanism, not yet assessed in prior research. Forty-eight male Albino mice were divided into six groups: Group I (normal control), group II (Ulcer/ethanol control), group III (Omeprazole + ethanol), group IV (fucoidan 25 mg + ethanol), group V (fucoidan 50 mg + ethanol) and group VI (fucoidan only). Fucoidan was administered orally for seven consecutive days followed by ulcer induction by a single oral dose of ethanol. Using colorimetric analysis, ELISA, qRT-PCR, histological assessment, and immunohistochemical studies, the results revealed that ethanol-induced ulcer exhibited an ulcer score of 42.5 ± 5.1 and a significant increase (p < 0.05) in malondialdehyde (MDA), nuclear factor kappa B (NF-κB), and interleukin 6 (IL-6) with a significant decrease in the gastro-protective mediators, prostaglandin E2 (PGE2), superoxide dismutase (SOD) and glutathione (GSH), accompanied with an increase in NLRP3, interleukin 1β (IL-1β), interleukin 18 (IL-18), caspase 1, caspase 11, gasdermin D, and toll-like receptor 4 (TLR4), compared with the normal control. Pre-treatment with fucoidan showed a comparable result with omeprazole. Additionally, pre-treatments elevated the levels of the gastro-protective mediators and lessened oxidative stress, relative to the positive control findings. Conclusively, fucoidan has a promising gastro-protective role by inhibiting inflammation and pyroptosis.

Fucoidan in Pharmaceutical Formulations: A Comprehensive Review for Smart Drug Delivery Systems

Fucoidan is a heterogeneous group of polysaccharides isolated from marine organisms, including brown algae and marine invertebrates. The physicochemical characteristics and potential bioactivities of fucoidan have attracted substantial interest in pharmaceutical industries in the past few decades. These polysaccharides are characterized by possessing sulfate ester groups that impart negatively charged surfaces, low/high molecular weight, and water solubility. In addition, various promising bioactivities have been reported, such as antitumor, immunomodulatory, and antiviral effects. Hence, the formulation of fucoidan has been investigated in the past few years in diverse pharmaceutical dosage forms to be able to reach their site of action effectively. Moreover, they can act as carriers for various drugs in value-added drug delivery systems. The current work highlights the attractive biopharmaceutical properties of fucoidan being formulated in oral, inhalable, topical, injectable, and other advanced formulations treating life-quality-affecting diseases. Therefore, the present work points out the current status of fucoidan pharmaceutical formulations for future research transferring their application from in vitro and in vivo studies to clinical application and market availability.

Fucoidan-ferulic acid nanoparticles alleviate cisplatin-induced acute kidney injury by inhibiting the cGAS-STING pathway

Fucoidan (FU) is a natural sulfated polysaccharide with certain biological activity and has been shown to be an excellent nano-delivery material. In this study, ferulic acid (FA)-loaded FU nanoparticles (FA/FU NPs) were prepared and their nephroprotective mechanism was investigated. With a particle size of 158.6 ± 4.5 nm, FA/FU NPs increased the antioxidant activity of FA in vitro, possibly related to the increased dispersity of FA. In vitro results demonstrated that FA/FU NPs significantly protected human renal proximal tubule (HK-2) cells from cisplatin-induced damage, possibly by suppressing cisplatin-induced DNA damage and activating the cGAS-STING pathway. Furthermore, in vivo experiments confirmed that FA/FU NPs protected mice from cisplatin-induced acute kidney injury (AKI). Mechanistic studies confirmed that FA/FU NPs exerted nephroprotective effects by reducing MDA activity and increasing GSH and SOD activity. Our results demonstrated the potential of FU for delivering poorly soluble drug FA and protecting against cisplatin-induced AKI.

Insight into Fucoidan-Based PEGylated PLGA Nanoparticles Encapsulating Methyl Anthranilic Acid: In Vitro Evaluation and In Vivo Anti-Inflammatory Study

A potential fucoidan-based PEGylated PLGA nanoparticles (NPs) offering a proper delivery of N-methyl anthranilic acid (MA, a model of hydrophobic anti-inflammatory drug) have been developed via the formation of fucoidan aqueous coating surrounding PEGylated PLGA NPs. The optimum formulation (FuP2) composed of fucoidan:m-PEG-PLGA (1:0.5 w/w) with particle size (365 ± 20.76 nm), zeta potential (-22.30 ± 2.56 mV), % entrapment efficiency (85.45 ± 7.41), drug loading (51.36 ± 4.75 µg/mg of NPs), % initial burst (47.91 ± 5.89), and % cumulative release (102.79 ± 6.89) has been further investigated for the anti-inflammatory in vivo study. This effect of FuP2 was assessed in rats' carrageenan-induced acute inflammation model. The average weight of the paw edema was significantly lowered (p ≤ 0.05) by treatment with FuP2. Moreover, cyclooxygenase-2 and tumor necrosis factor-alpha immunostaining were decreased in FuP2 treated group compared to the other groups. The levels of prostaglandin E2, nitric oxide, and malondialdehyde were significantly reduced (p ≤ 0.05) in the FuP2-treated group. A significant reduction (p ≤ 0.05) in the expression of interleukins (IL-1β and IL-6) with an improvement of the histological findings of the paw tissues was observed in the FuP2-treated group. Thus, fucoidan-based PEGylated PLGA-MA NPs are a promising anti-inflammatory delivery system that can be applied for other similar drugs potentiating their pharmacological and pharmacokinetic properties.

Sulfated Galactofucans: An Outstanding Class of Fucoidans with Promising Bioactivities

Fucoidans encompass versatile and heterogeneous sulfated biopolysaccharides of marine origin, specifically brown algae and marine invertebrates. Their chemistry and bioactivities have been extensively investigated in the last few decades. The reported studies revealed diverse chemical skeletons in which l-fucose is the main sugar monomer. However, other sugars, i.e., galactose, mannose, etc., have been identified to be interspersed, forming several heteropolymers, including galactofucans/fucogalactans (G-fucoidans). Particularly, sulfated galactofucans are associated with rich chemistry contributing to more promising bioactivities than fucans and other marine polysaccharides. The previous reports in the last 20 years showed that G-fucoidans derived from Undaria pinnatifida were the most studied; 21 bioactivities were investigated, especially antitumor and antiviral activities, and unique biomedical applications compared to other marine polysaccharides were demonstrated. Hence, the current article specifically reviews the biogenic sources, chemistry, and outstanding bioactivities of G-fucoidans providing the opportunity to discover novel drug candidates.

Antiviral Activities of Algal-Based Sulfated Polysaccharides

An antiviral agent is urgently needed based on the high probability of the emergence and re-emergence of future viral disease, highlighted by the recent global COVID-19 pandemic. The emergence may be seen in the discovery of the Alpha, Beta, Gamma, Delta, and recently discovered Omicron variants of SARS-CoV-2. The need for strategies besides testing and isolation, social distancing, and vaccine development is clear. One of the strategies includes searching for an antiviral agent that provides effective results without toxicity, which is well-presented by significant results for carrageenan nasal spray in providing efficacy against human coronavirus-infected patients. As the primary producer of sulfated polysaccharides, marine plants, including macro- and microalgae, offer versatility in culture, production, and post-isolation development in obtaining the needed antiviral agent. Therefore, this review will describe an attempt to highlight the search for practical and safe antiviral agents from algal-based sulfated polysaccharides and to unveil their features for future development.

Fucoidan Characterization: Determination of Purity and Physicochemical and Chemical Properties

Fucoidans are marine sulfated biopolysaccharides that have heterogenous and complicated chemical structures. Various sugar monomers, glycosidic linkages, molecular masses, branching sites, and sulfate ester pattern and content are involved within their backbones. Additionally, sources, downstream processes, and geographical and seasonal factors show potential effects on fucoidan structural characteristics. These characteristics are documented to be highly related to fucoidan potential activities. Therefore, numerous chemical qualitative and quantitative determinations and structural elucidation methods are conducted to characterize fucoidans regarding their physicochemical and chemical features. Characterization of fucoidan polymers is considered a bottleneck for further biological and industrial applications. Consequently, the obtained results may be related to different activities, which could be improved afterward by further functional modifications. The current article highlights the different spectrometric and nonspectrometric methods applied for the characterization of native fucoidans, including degree of purity, sugar monomeric composition, sulfation pattern and content, molecular mass, and glycosidic linkages.

Fucoidans: Downstream Processes and Recent Applications

Fucoidans are multifunctional marine macromolecules that are subjected to numerous and various downstream processes during their production. These processes were considered the most important abiotic factors affecting fucoidan chemical skeletons, quality, physicochemical properties, biological properties and industrial applications. Since a universal protocol for fucoidans production has not been established yet, all the currently used processes were presented and justified. The current article complements our previous articles in the fucoidans field, provides an updated overview regarding the different downstream processes, including pre-treatment, extraction, purification and enzymatic modification processes, and shows the recent non-traditional applications of fucoidans in relation to their characters.

Chitosan-toluidine blue beads for purification of fucoidans

A simple and green method was developed to purify fucoidans from their crude extracts. The new method utilizes a genipin-crosslinked chitosan beads as a support matrix for toluidine blue (TB). The modification of the mostly composed of d-glucosamine polymer was performed in one-step reaction to improve its mechanical stability and affinity to fucoidans. The adsorption kinetics and isotherm were investigated, which showed a maximum loading capacity (q_max) of 137.8 mg fucoidans/g wet beads. Moreover, the modified chitosan-TB beads were applied for purification of fucoidans from Fucus vesiculosus crude extract at different pH values, pH 1.0 and pH 6.0, producing two fractions: FC_1 and FC_6, respectively. The fractions were then characterized in comparison with crude and Sigma-Aldrich® purified product by FTIR and elemental analysis. The new method produced beads with higher loading capacity and used a natural crosslinker compared to the previously-reported methods.

Fucoidan isolated from Padina commersonii inhibit LPS-induced inflammation in macrophages blocking TLR/NF-κB signal pathway

Brown seaweeds are well-known source of bioactive compounds, which are producing a variety of secondary metabolites with promising bioactive properties. Traditionally, seaweeds used as ingredients in medicine for many centuries in Asian countries. However, the protective mechanisms of many metabolites found in seaweeds are remains to be determined. Thus, applications of seaweeds are limited because of poor understanding of their structural features and mechanisms responsible for their bioactive properties. In the present study, anti-inflammatory properties of fucoidan isolated from the brown seaweed Padina commersonii (PCF) was evaluated against LPS-activated RAW 264.7 macrophages. PCF was characterized using NMR, FT-IR, and HPAE-PAD spectrum (for mono sugar composition). It was observed that PCF is rich in fucose and sulfate as well as a similar structure to the commercial fucoidan. Western blots and RT-qPCR analysis were used to determine the protective effects of PCF after LPS challenge using RAW 264.7 macrophages. According to the results, PCF significantly down-regulated LPS-activated mRNA and protein expression levels of TLR2, TLR4, and MyD88 which are known inducers/activators of NF-κB transcriptional factors. The results, obtained from this study demonstrated PCF has a potential to inhibit LPS-induced inflammatory responses via blocking TLR/MyD88/ NF-κB signal transduction.